IL3 and systemic lupus erythematosus: As specific antibody-mediated basophil depletion in humans is not yet available, acting on basophil activation through IL-3 blockade43,46, anti-IgEapproach23,65, or preventing basophil accumulation in SLO through PTGDRs antagonisms15,21 represent a promising area of clinical development that may provide to SLE patients some new specific and efficient therapeutic options.